Lykos 2013
Lykos 2013 is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Lykos 2013.
Lykos 2013 is a company.
Key people at Lykos 2013.
Key people at Lykos 2013.
Lykos 2013 refers to multiple distinct companies founded or incorporated around 2013, but the most prominent and relevant entity matching the query appears to be Lykos Therapeutics, a public benefit corporation focused on developing MDMA-assisted therapies for mental health. Another unrelated entity is Inform P. Lykos SA, a European company specializing in smart card production and information management, but it was established earlier and is unrelated to the 2013 founding date. Additionally, there are smaller companies named Lykos India Private Limited and Lykos Group Ltd., but these are private firms in different sectors with limited public information.
---
Lykos Therapeutics is a public benefit corporation dedicated to transforming mental healthcare by developing MDMA (commonly known as ecstasy) for medicinal use, particularly targeting mental health conditions such as post-traumatic stress disorder (PTSD). It serves patients, therapists, and the broader mental health ecosystem by providing innovative psychedelic-assisted therapeutic options. The company aims to address the unmet needs in mental health treatment through evidence-based psychedelic research, striving to destigmatize mental health and expand treatment tools[1][3].
---
Lykos Therapeutics was founded in 2014 as the MAPS Public Benefit Corporation (MAPS PBC) by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). It was renamed Lykos Therapeutics in January 2024. The company emerged from decades of psychedelic research led by MAPS, focusing on advancing MDMA-assisted psychotherapy through clinical trials and regulatory approval processes. The company faced significant challenges, including FDA setbacks in 2024, leading to workforce reductions and leadership changes. In early 2025, billionaire investor Antonio Gracias initiated a takeover effort to revitalize the company and strengthen its ties with MAPS to push toward FDA approval[1].
---
---
Lykos Therapeutics is riding the psychedelic renaissance trend in mental healthcare, where renewed scientific interest and regulatory openness are enabling psychedelic compounds to be reconsidered as legitimate treatments. The timing is critical as mental health disorders remain a global crisis with limited effective treatments. Market forces such as increasing mental health awareness, demand for innovative therapies, and evolving FDA policies favor Lykos’ mission. The company influences the broader ecosystem by advancing clinical research, shaping regulatory frameworks, and fostering acceptance of psychedelic therapies in mainstream medicine[1][3].
---
Lykos Therapeutics faces a pivotal future as it attempts to secure FDA approval for MDMA-assisted psychotherapy, which could revolutionize mental health treatment paradigms. The involvement of high-profile investors and renewed strategic focus suggests potential for growth and impact. Trends shaping its journey include regulatory shifts, expanding mental health markets, and increasing societal acceptance of psychedelics. If successful, Lykos could become a leader in a new class of psychiatric treatments, significantly influencing both healthcare and biotech innovation landscapes.
---
This overview focuses on Lykos Therapeutics, the most notable "Lykos 2013" entity in public and investment contexts. Other companies named Lykos exist but are unrelated in sector or scale.
